Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?
Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions
Appropriate Categorization of Inequality to Inform Policy Decisions: Estimating Distribution of Lifetime Health Using Alternative Approaches to Socioeconomic Stratification
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival
Two Methods, One Story? Comparing Results of a Choice Experiment and Multidimensional Thresholding From a Clinician Preference Study in Aneurysmal Subarachnoid Hemorrhage
Applying Trial-Derived Treatment Effects to Real-World Populations: Generalizing Cost-Effectiveness Estimates When Modeling Complex Hazards
Patient-Reported Outcome-Based Performance Measures in Alternative Payment Models: Current Use, Implementation Barriers, and Principles to Succeed
Microsimulation Models on Mental Health: A Critical Review of the Literature
Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs
Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology
Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients
Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report
Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study
Public Acceptance of Measures to Control Infectious Diseases Under Different Scenarios of Severity and Transmissibility
It Is Time to Reconsider the 3% Discount Rate
Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps
Perspectives on Improving Value Assessment With the ISPOR SUITABILITY Checklist
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force
Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses
Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access
Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)
Methods to Include Environmental Impacts in Health Economic Evaluations and Health Technology Assessments: A Scoping Review
Social Decision-Making Analysis: A General Approach to Inform Decisions on Resources in the Public Sector
Values Beyond “Health” in Budget-Constrained Healthcare Systems
From Health to Well-Being: Toward a Monetary Valuation of a Well-Being-Adjusted Life-Year
Construct Validity, Reliability, and Responsiveness of the 10-Item Well-Being Instrument for Use in Economic Evaluation Studies
Testing the Psychometric Properties of 9 Bolt-Ons for the EQ-5D-5L in a General Population Sample
Comparison of the EQ-HWB and EQ-HWB-S With Other Preference-Based Measures Among United States Informal Caregivers
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States
Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals
It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties
Health Fluctuations in Dementia and its Impact on the Assessment of Health-Related Quality of Life Using the EQ-5D-5L
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review
A Roadmap for Improving Medicare’s Application of Coverage With Evidence Development
Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI)
Psychometric Performance of the EQ Health and Wellbeing Short in a United Kingdom Population Sample
Testing “Pits” Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now
×